Corrigendum

Corrigendum to “Pharmacogenetics of Risperidone and Cardiovascular Risk in Children and Adolescents”

Amilton Dos Santos-Júnior,¹ Taciane Barbosa Henriques,² Maricilda Palandi de Mello,² Osmar Henrique Della Torre,¹ Lúcia Arisaka Paes,¹ Adriana Perez Ferreira-Neto,¹ Letícia Esposito Sewaybricker,³ Thiago Salum Fontana,¹ Eloisa Helena Rubello Valler Celeri,¹ Gil Guerra-Júnior,^{3,4} and Paulo Dalgalarrrondo¹

¹Department of Psychiatry, School of Medical Sciences (FCM), State University of Campinas (Unicamp), 13083-887 Campinas, SP, Brazil

²Laboratory of Human Genetics, Center for Molecular Biology and Genetic Engineering (CBMEG), Unicamp, 13083-875 Campinas, SP, Brazil

³Growth and Development Laboratory, Center for Investigation in Pediatrics (CIPED), FCM-Unicamp, 13083-887 Campinas, SP, Brazil

⁴Department of Pediatrics, Pediatric Endocrinology Unit, FCM-Unicamp, 13083-887 Campinas, SP, Brazil

Correspondence should be addressed to Osmar Henrique Della Torre; dr.osmar.psiq@gmail.com

Received 5 January 2017; Accepted 19 April 2017; Published 16 May 2017

Copyright © 2017 Amilton Dos Santos-Júnior et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In the article titled “Pharmacogenetics of Risperidone and Cardiovascular Risk in Children and Adolescents” [1], there was an error in the “Laboratory Evaluation” section, where the selected CYP2D6 SNP is written as rs72552269, and should be corrected to “rs1065852.”

Reference

- [1] A. D. Santos-Júnior, T. B. Henriques, M. P. de Mello et al., “Pharmacogenetics of risperidone and cardiovascular risk in children and adolescents,” *International Journal of Endocrinology*, vol. 2016, Article ID 5872423, 10 pages, 2016.